Heartflow Receives ACC and AHA Endorsement for AI Coronary Plaque Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Newsfilter
- Technology Endorsement: Heartflow's AI-powered plaque analysis tool has received support from the ACC and AHA scientific statements, emphasizing its critical role in coronary artery disease management, marking a shift from emerging technology to clinical standard, which is expected to enhance widespread clinical adoption.
- Clinical Impact: Research indicates that Heartflow Plaque Analysis changed medical management decisions in over 50% of patients, highlighting its pivotal role in personalized treatment plans and potentially improving patient outcomes significantly.
- Data Foundation: Heartflow's proprietary data pipeline, built from over 110 million annotated CTA images, empowers its AI models to deliver highly accurate clinical insights, further solidifying its application across more than 1,400 institutions globally.
- Quality Standards: Heartflow's technology meets or exceeds leading international standards, including HITRUST and ISO 13485, ensuring patient data security and integrity, which enhances trust among healthcare institutions in its products.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HTFL is 38.60 USD with a low forecast of 35.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.980
Low
35.00
Averages
38.60
High
40.00
Current: 34.980
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
